Exopharm Limited is a clinical stage company at the forefront of developing transformative medicines based upon exosomes (EVs). Dosing of the 11 participants in PLEXOVAL II has completed and final follow-up medical appointments with all test subjects are also completed. No adverse events related to the treatment using Plexaris or the placebo were reported. The data will now be analysed by an independent third party with final results expected by around March 2021. Engineered EV (EEVs) are a way to deliver important new drugs and overcome limitations of other delivery technologies. EEVs can be designed and made to deliver drugs (such as mRNA or proteins) to specific cell types - a trait referred to as `tropism'. Exopharm's EVPS technology patent for tropism has been granted by the US Patent and Trademark Office. EVs are of interest to biopharmaceutical and big pharma companies as solutions to the delivery problems they experience with many drug candidates. Using EVs as an improved delivery vehicle could `unlock' previous investments in unsuccessfully delivered drugs. Exopharm's recent partnering discussions cover the use of its EEV technologies and use of its LEAP manufacturing technology. To support potential partners with operations in Europe, Exopharm is establishing a wholly-owned Swiss entity, Exopharm GmbH, in Basel, Switzerland and locating two of its people in Europe. Since Exopharm's in-depth presentation of the LEAPTM technology at the Exosome Based Therapeutic Development Summit in November 2020, discussions with collaborators and business partners have accelerated. In January and February Exopharm will be presenting its business and science to audiences in Japan, the UK, the US and Australia.